



VACCINE ACCESS TEST

Score Summary: France

The world is racing to find safe and effective vaccines against COVID-19. And when we do, these vaccines must be made available to everyone who needs them regardless of nationality or wealth. This is the fastest way to end the pandemic. So we want to know: **do world leaders' actions move us closer to, or further from, an equitable outcome?** The Vaccine Access Test provides a framework to answer this question based on the following metrics:

- **Access to COVID-19 Tools Accelerator (ACT-A):** Has this country provided financial support to the ACT-A?
- **Multilateral Leadership:** Has this country advanced multilateral cooperation to advance equity?
- **Policies:** Will this country's policies help ensure COVID-19 vaccines are accessible to all on a global scale?

Each metric is worth up to 3 points with a possible 9 points total. **Here's how France stacks up.**

METRIC	SCORE	RATIONALE
ACT-A 	0	France has contributed €110 million to the ACT-A.
Multilateral Leadership 	2	France co-hosted the Coronavirus Global Pledging Moment in May 2020 and France has joined the COVAX facility as part of Team Europe.
Policies 	1	France has not implemented policies that align with WHO's Solidarity Call to Action; France has guidelines on domestic allocation that prioritizes the most-at risk.

Total Score: 3 out of 9

France's actions so far have proven a dedication to equitable outcomes, but have not gone far enough. France has shown its commitment by pledging financially to the ACT-A but its contribution still remains too low to reach its fair share.

President Macron made a welcome commitment to making the COVID-19 vaccine a global public good in an op-ed published in May 2020 and co-signed by other European partners as well as in several public speeches, but should go a step further. Having delegated vaccine procurement to the EU, France can improve its score by pressing for European deals with pharmaceutical companies to be more transparent, and that procurement contracts align with the WHO's Allocation Guidance to ensure the initial supply is not monopolized by France or the EU so there is adequate supply for other countries. France should also sign onto the WHO's Solidarity Call to Action and work with French pharmaceutical companies to secure voluntary licencing for all COVID-19 tools they will develop.



▲ Impeding Equity

Advancing Equity ▲